Cambridge startup Tolemy Bio and California's GeminiBio unite for cell therapy mission
Tolemy Bio is based at The Future Business Centre in Cambridge and has laboratory facilities at The EpiCentre in Haverhill.
The technology the duo have just launched is branded aiMOS™ (Artificial Intelligence Media Optimisation Service) designed to leverage AI and ML plus multi‑omics data to design custom media supplements that improve the performance, consistency, and scalability of cell therapy manufacturing.
Gemini Bioproducts, LLC is a biopharma and advanced therapy raw materials supplier and a portfolio company of BelHealth Investment Partners. The service developed in collaboration with Tolemy Bio is designed to help cell therapy innovators improve their biology, enhance critical quality attributes (CQAs), increase manufacturing efficiency and reduce overall cost across T‑cell, NK‑cell, TCR, and TIL development and manufacturing processes.
GeminiBio provides serum, customised media, buffers and process liquids to biopharma and advanced therapy companies focused on the research and production of mRNA, AAV, monoclonal antibody, and cell therapy technologies.
For more than a decade, its human AB serum has been widely adopted as a key supplement in cell-therapy workflows, supporting robust immune-cell expansion in both clinical development and commercial manufacturing.
aiMOS builds on this foundation by shifting from general supplementation to data-driven, process-specific media optimisation that enhances a customer’s base media and unlocks targeted cell therapy performance improvements.
“Cell therapy developers shouldn’t have to accept one‑size‑fits‑all media when their processes, cell sources, and activation strategies are so different,” said Brian Parker, Chief Executive Officer at GeminiBio.
“aiMOS reads what the cells are telling us in culture, designs a tailored media supplement, and then takes that formulation all the way to cGMP—so developers can improve CQAs, reduce batch variability, and lower cost per dose without disrupting their base media choice.”
Alex Ward, co‑founder at Tolemy Bio added: “By applying causal AI modelling to a cell’s metabolic and behavioral fingerprints, our platform can identify the exact levers that drive cell therapy performance, potency and yield.
“With that information, we can then predict the ideal supplement composition and concentrations to specifically enhance cell performance. Paired with GeminiBio’s cGMP manufacturing and custom filling capabilities, aiMOS gives cell therapy developers a practical, high-impact way to achieve better performance—with full confidence to scale from early development through commercialisation.”
By improving viable yields, supporting more favourable phenotypes (e.g., memory‑like T cells), and stabilising batch‑to‑batch performance, aiMOS can help cell therapy developers:
• Drive superior performance by tailoring supplementation to the specific needs of each cell type
• Lower cost per dose by reducing failed or underperforming batches, limiting rework, and optimising cytokine/reagent usage
• Shorten development timelines by avoiding iterative, trial‑and‑error media tuning
• Scale with confidence from research to late‑stage clinical and commercial manufacturing
aiMOS is available immediately to cell therapy developers worldwide. For more information, visit www.geminibio.com or contact info@geminibio.com.
Tolemy Bio, a TechBio business, is building Orbit, an AI-native control panel for the cell that helps teams design, optimise and control cell culture processes for advanced therapeutic development and production. Orbit ingests messy experimental and manufacturing data, such as cell growth, phenotype, potency and metabolite readouts, then applies cell-type specific causal AI models to identify key biological levers that drive cellular performance.
By turning complex datasets into actionable process and media recommendations, Tolemy Bio helps therapy developers improve critical quality attributes (CQAs), reduce variability, and accelerate development from early R & D through scalable manufacturing, bringing life-saving cell therapies to patients faster with AI.
